Onkure Therapeutics Inc (OKUR) Kazanmak

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company is headquartered in Boulder, Colorado and currently employs 45 full-time employees. The company went IPO on 2021-04-09. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. The company is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. The company is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. The company is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. The company also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.